Charles L. Crespi

9.9k citations

97 papers · 7.8k indexed · 3 hit papers · h-index 44

Pharmacology top 0.02%
Molecular Biology top 5%
Oncology top 1%
Cancer Research top 1%
Health, Toxicology and Mutagenesis top 0.5%

Co-authors: Bruce W. Penman Vaughn P. Miller William F. Busby David J. Waxman Frank J. Gonzalez Thomas K. H. Chang Arthur L. Lafleur Harry V. Gelboin
Topics: Pharmacogenetics and Drug Metabolism (61 papers)Carcinogens and Genotoxicity Assessment (31 papers)Drug Transport and Resistance Mechanisms (23 papers)
Cited by: Pharmacology Health, Toxicology and Mutagenesis Biochemistry
Journals: Proceedings of the National Academy of Sciences Environmental Science & Technology Analytical Biochemistry
Partner nations: United States Canada United Kingdom

In The Last Decade

Charles L. Crespi

97 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA damage and mutation in human cells exposed to nitric oxide in vitro.

1992 806 citations Charles L. Crespi, Bruce W. Penman et al. profile →
Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols

1996 713 citations John L. Durant, William F. Busby et al. Mutation Research/Genetic Toxicology profile →
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

1993 457 citations Thomas K. H. Chang, Charles L. Crespi et al. profile →

Peers

Countries citing papers authored by Charles L. Crespi

Since Specialization

Citations

This map shows the geographic impact of Charles L. Crespi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles L. Crespi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles L. Crespi more than expected).

Fields of papers citing papers by Charles L. Crespi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles L. Crespi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles L. Crespi. The network helps show where Charles L. Crespi may publish in the future.

Co-authorship network of co-authors of Charles L. Crespi

This figure shows the co-authorship network connecting the top 25 collaborators of Charles L. Crespi. A scholar is included among the top collaborators of Charles L. Crespi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles L. Crespi. Charles L. Crespi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Multi-Endpoint Evaluation of Cytochrome P450 1A2, 2B6 and 3A4 Induction Response in Human Hepatocyte Cultures After Treatment with β - Naphthoflavone, Phenobarbital and Rifampicin 2010 ·Drug Metabolism Letters ·George Zhang,(unknown),(unknown),Charles L. Crespi,David M. Stresser	26
2	Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine 2009 ·Drug Metabolism and Disposition ·David M. Stresser,(unknown),Elke S. Perloff,(unknown),Charles L. Crespi,Andre Dandeneau,(unknown),Shangara S. Dehal	16
3	HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 2006 ·Drug Metabolism and Disposition ·George Zhang,Shangara S. Dehal,(unknown),Jennifer Johnson,(unknown),Andrew P. Blanchard,R. J. H. Clark,Charles L. Crespi,David M. Stresser,(unknown)	34
4	HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE 2004 ·Drug Metabolism and Disposition ·David M. Stresser,(unknown),(unknown),(unknown),Andrew P. Blanchard,Raman Sharma,Andre Dandeneau,(unknown),Stephanie D. Turner,John C. L. Erve,Christopher Patten,Shangara S. Dehal,Charles L. Crespi	115
5	High-Performance Liquid Chromatographic Analysis of CYP2CSCatalyzed Paclitaxel 6α-Hydroxylation 2003 ·Humana Press eBooks ·Charles L. Crespi,Thomas K. H. Chang,David J. Waxman	2
6	Spectrophotometric Analysis of Human CY P2El -Catalyzed pNitrophenol Hydroxylation 2003 ·Humana Press eBooks ·Thomas K. H. Chang,Charles L. Crespi,David J. Waxman	56
7	Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine 2002 ·Drug Metabolism and Disposition ·Kenda Marcucci,Robin E. Pearce,Charles L. Crespi,Dorothy T. Steimel,J. Steven Leeder,Andrea Gaedigk	53
8	Thiourea toxicity in mouse C3H/10T12 cells expressing human flavin-dependent monooxygenase 3 2002 ·Biochemical Pharmacology ·P.Blaise Smith,Charles L. Crespi	38
9	Effect of Methanol, Ethanol, Dimethyl Sulfoxide, and Acetonitrile on In Vitro Activities of cDNA-Expressed Human Cytochromes P-450 1999 ·Drug Metabolism and Disposition ·William F. Busby,(unknown),Charles L. Crespi	245
10	Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions 1997 ·Advances in pharmacology ·Charles L. Crespi,Bruce W. Penman	101
11	Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens 1997 ·Mutagenesis ·Charles L. Crespi,(unknown),Dorothy T. Steimel,Theresa J. Smith,Chung S. Yang,Thomas R. Sutter	96
12	Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosolsbreakdown → 1996 ·Mutation Research/Genetic Toxicology ·John L. Durant,William F. Busby,Arthur L. Lafleur,Bruce W. Penman,Charles L. Crespi	713
13	Mutagenicity of benzo[a]pyrene and dibenzopyrenes in the Salmonella typhimurium TM677 and the MCL-5 human cell forward mutation assays 1995 ·Mutation Research/Genetic Toxicology ·William F. Busby,(unknown),Charles L. Crespi,Bruce W. Penman	67
14	Human cell lines, derived from AHH-1 TK+/− human lymphoblasts, genetically engineered for expression of cytochromes P450 1993 ·Toxicology ·Charles L. Crespi,Robert Langenbach,(unknown)	61
15	Recombinant DNA approaches for the development of metabolic systems used in in vitro toxicology 1992 ·Mutation Research/Reviews in Genetic Toxicology ·Robert Langenbach,P.Blaise Smith,Charles L. Crespi	40
16	The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B₁ and comparison to CYP1A2 and CYP2A3 1991 ·Carcinogenesis ·Charles L. Crespi,Bruce W. Penman,Dorothy T. Steimel,Harry V. Gelboin,Frank J. Gonzalez	107
17	A tobacco smoke-derived nitrosamine, 4-(methytnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytocbrome P450s including the polymorphic human cytochrome P4502D6 1991 ·Carcinogenesis ·Charles L. Crespi,(unknown),Harry V. Gelboin,Frank J. Gonzalez	191
18	Stable expression of human cytochrome P450IA2 cDNA in a human lymphoblastoid cell line: Role of the enzyme in the metabolic activation of aflatoxin B₁ 1990 ·Molecular Carcinogenesis ·Charles L. Crespi,Dorothy T. Steimel,Toshifumi Aoyama,Harry V. Gelboin,Frank J. Gonzalez	36
19	Development of a human cell line by selection and drug-metabolizing gene transfection with increased capacity to activate promutagens 1989 ·Carcinogenesis ·Robert L. Davies,Charles L. Crespi,(unknown),Thomas R. Turner,Robert Langenbach	50
20	The mutagenic activity of selected compounds at the TK locus: Rodent vs. human cells 1988 ·Mutation Research/Reviews in Genetic Toxicology ·William J. Caspary,Robert Langenbach,Bruce W. Penman,Charles L. Crespi,B. Myhr,Ann D. Mitchell	24

About Charles L. Crespi

Charles L. Crespi is a scholar working on Pharmacology, Cancer Research and Biochemistry, having authored 97 papers that have together received 7.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (61 papers), Carcinogens and Genotoxicity Assessment (31 papers) and Drug Transport and Resistance Mechanisms (23 papers). The work is most often cited by research in Pharmacology (3.5k citations), Health, Toxicology and Mutagenesis (1.2k citations) and Biochemistry (605 citations). Charles L. Crespi has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Bruce W. Penman, Vaughn P. Miller, William F. Busby, David J. Waxman, Frank J. Gonzalez, Thomas K. H. Chang, Arthur L. Lafleur, Harry V. Gelboin, David M. Stresser and John L. Durant. Their work appears in journals such as Proceedings of the National Academy of Sciences, Environmental Science & Technology and Analytical Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact